

# Eric Delaporte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268374/publications.pdf>

Version: 2024-02-01

360  
papers

16,086  
citations

15504

65  
h-index

30922

102  
g-index

371  
all docs

371  
docs citations

371  
times ranked

11209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context. <i>Journal of Infectious Diseases</i> , 2022, 226, 352-356.	4.0	5
2	Dynamics of Antibodies to Ebolaviruses in an Eidolon helvum Bat Colony in Cameroon. <i>Viruses</i> , 2022, 14, 560.	3.3	7
3	High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac152.	0.9	8
4	Seroprevalence of IgG Antibodies Against Multiple Arboviruses in Bats from Cameroon, Guinea, and the Democratic Republic of Congo. <i>Vector-Borne and Zoonotic Diseases</i> , 2022, , .	1.5	2
5	Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui). <i>Clinical Infectious Diseases</i> , 2021, 73, 2166-2174.	5.8	12
6	Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo. <i>Nature Medicine</i> , 2021, 27, 710-716.	30.7	35
7	Investigating the Circulation of Ebola Viruses in Bats during the Ebola Virus Disease Outbreaks in the Equateur and North Kivu Provinces of the Democratic Republic of Congo from 2018. <i>Pathogens</i> , 2021, 10, 557.	2.8	13
8	Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e676-e684.	7.3	10
9	Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. <i>Nature</i> , 2021, 597, 539-543.	27.8	113
10	Multiplex detection of antibodies to Chikungunya, Oâ€™nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-human primate species from Cameroon and the Democratic Republic of Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009028.	3.0	18
11	Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). <i>Pharmacoeconomics</i> , 2021, 39, 331-343.	3.3	10
12	Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. <i>Aids</i> , 2020, 34, 783-787.	2.2	7
13	Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. <i>Lancet HIV</i> , the, 2020, 7, e677-e687.	4.7	86
14	Wide Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in Guinea, West Africa. <i>Viruses</i> , 2020, 12, 855.	3.3	20
15	Long-lasting severe immune dysfunction in Ebola virus disease survivors. <i>Nature Communications</i> , 2020, 11, 3730.	12.8	33
16	Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati), Democratic Republic of the Congo, 2017. <i>Emerging Infectious Diseases</i> , 2020, 26, 2205-2209.	4.3	19
17	High HIV burden and recent transmission chains in rural forest areas in southern Cameroon, where ancestors of HIV-1 have been identified in ape populations. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104358.	2.3	1
18	Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. <i>Journal of Clinical Virology</i> , 2020, 129, 104521.	3.1	68

#	ARTICLE	IF	CITATIONS
19	Advances in clinical trial design: Weaving tomorrow's TB treatments. <i>PLoS Medicine</i> , 2020, 17, e1003059.	8.4	16
20	Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS) Tj ETQq0 0 0,rgBT /Overlock 10 T	2.9	4
21	Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions. <i>Clinical Infectious Diseases</i> , 2019, 68, 330-333.	5.8	39
22	Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. <i>New England Journal of Medicine</i> , 2019, 381, 816-826.	27.0	196
23	Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. <i>BMC Nephrology</i> , 2019, 20, 155.	1.8	22
24	Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. <i>Clinical Infectious Diseases</i> , 2019, 70, 1471-1477.	5.8	1
25	Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 648-657.	9.1	62
26	2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 641-647.	9.1	27
27	Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 308-316.	9.1	36
28	A 40 months follow-up of Ebola virus disease survivors in Guinea (Postebogui) reveals longterm detection of Ebola viral RNA in semen and breast milk. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz482.	0.9	26
29	Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007812.	3.0	20
30	Extensive Serological Survey of Multiple African Nonhuman Primate Species Reveals Low Prevalence of Immunoglobulin G Antibodies to 4 Ebola Virus Species. <i>Journal of Infectious Diseases</i> , 2019, 220, 1599-1608.	4.0	23
31	Implementation and evaluation of a therapeutic patient education programme during a clinical trial in Yaoundé, Cameroon - Trial ANRS-12286/MOBIDIP. <i>Patient Education and Counseling</i> , 2018, 101, 1262-1269.	2.2	0
32	Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supply-related factors (ANRS) Tj ETQq0 0 0,rgBT /Overlock 10 T	2.2	0
33	Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 477-480.	1.1	4
34	The fourth HIV epidemic. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 379-380.	9.1	15
35	Comparison of different nucleic acid preparation methods to improve specific HIV-1 RNA isolation for viral load testing on dried blood spots. <i>Journal of Virological Methods</i> , 2018, 251, 75-79.	2.1	23
36	Survey of Ebola Viruses in Frugivorous and Insectivorous Bats in Guinea, Cameroon, and the Democratic Republic of the Congo, 2015-2017. <i>Emerging Infectious Diseases</i> , 2018, 24, 2228-2240.	4.3	66

#	ARTICLE	IF	CITATIONS
37	ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015). PLoS ONE, 2018, 13, e0202984.	2.5	6
38	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Na <sup>+</sup> ve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. Frontiers in Microbiology, 2018, 9, 409.	3.5	46
39	Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast. Journal of Medical Microbiology, 2018, 67, 87-96.	1.8	16
40	First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS ONE, 2018, 13, e0191920.	2.5	14
41	Serological Evidence of Ebola Virus Infection in Rural Guinea before the 2014 West African Epidemic Outbreak. American Journal of Tropical Medicine and Hygiene, 2018, 99, 425-427.	1.4	6
42	Phyloepidemiological Analysis Reveals that Viral Divergence Led to the Paucity of Simian Immunodeficiency Virus SIVmus/gsn/mon Infections in Wild Populations. Journal of Virology, 2017, 91, .	3.4	7
43	Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infectious Diseases, The, 2017, 17, 545-552.	9.1	96
44	High Prevalences and a Wide Genetic Diversity of Simian Retroviruses in Non-human Primate Bushmeat in Rural Areas of the Democratic Republic of Congo. EcoHealth, 2017, 14, 100-114.	2.0	13
45	Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clinical Infectious Diseases, 2017, 64, 1788-1790.	5.8	22
46	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq0,0,0 rgBT /Overlock 1 e384-e392.	4.7	63
47	Characteristics of the musculoskeletal symptoms observed among survivors of Ebola virus disease in the Postebogui cohort in Guinea. Rheumatology, 2017, 56, 2068-2072.	1.9	17
48	Full Genome Characterization of a New Simian Immune Deficiency Virus Lineage in a Naturally Infected Cercopithecus ascanius whitesidei in the Democratic Republic of Congo Reveals High Genetic Diversity Among Red-Tailed Monkeys in Central and Eastern Africa. AIDS Research and Human Retroviruses, 2017, 33, 735-739.	1.1	1
49	Ocular Complications in Survivors of the Ebola Outbreak in Guinea. American Journal of Ophthalmology, 2017, 175, 114-121.	3.3	55
50	Reply. American Journal of Ophthalmology, 2017, 181, 180.	3.3	0
51	Depressive symptoms among survivors of Ebola virus disease in Conakry (Guinea): preliminary results of the PostEboGui cohort. BMC Psychiatry, 2017, 17, 127.	2.6	75
52	Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. Journal of Clinical Microbiology, 2017, 55, 165-176.	3.9	47
53	Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clinical Microbiology and Infection, 2017, 23, 412-413.	6.0	12
54	Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PLoS ONE, 2017, 12, e0174767.	2.5	16

#	ARTICLE	IF	CITATIONS
55	TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study. PLoS ONE, 2017, 12, e0186686.	2.5	1
56	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e9-e15.	2.1	23
57	High rates of virological failure and drug resistance in perinatally HIV-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. Journal of the International AIDS Society, 2016, 19, 20683.	3.0	64
58	In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa. Aids, 2016, 30, 2577-2589.	2.2	24
59	Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infectious Diseases, 2016, 3, ofw142.	0.9	19
60	Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets. Open Forum Infectious Diseases, 2016, 3, ofw233.	0.9	12
61	Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon. Journal of Virological Methods, 2016, 237, 121-126.	2.1	3
62	Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. AIDS Research and Human Retroviruses, 2016, 32, 1159-1162.	1.1	28
63	Molecular epidemiology reveals genetic diversity among 363 isolates of the <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> species complex in 61 Ivorian HIV-positive patients. Mycoses, 2016, 59, 811-817.	4.0	19
64	Getting pregnant in HIV clinical trials: women's choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials. HIV Clinical Trials, 2016, 17, 233-241.	2.0	4
65	Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of <i>Candida albicans</i> isolates from Yaoundé HIV-infected patients. Medical Mycology, 2016, 55, myw108.	0.7	5
66	Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infectious Diseases of Poverty, 2016, 5, 66.	3.7	125
67	Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon. Antiviral Therapy, 2016, 21, 547-552.	1.0	1
68	Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial. Antiviral Therapy, 2016, 22, 195-203.	1.0	2
69	New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors: Table 1.. Journal of Infectious Diseases, 2016, 214, 1475-1476.	4.0	70
70	Genetic diversity of STLV-2 and interspecies transmission of STLV-3 in wild-living bonobos. Virus Evolution, 2016, 2, vew011.	4.9	8
71	High Rates of Drug Resistance Among Newly Diagnosed HIV-infected Children in the National Prevention of Mother-to-child Transmission Program in Togo. Pediatric Infectious Disease Journal, 2016, 35, 879-885.	2.0	14
72	Genetic diversity and transmission networks of HIV-1 strains among men having sex with men (MSM) in Lomé, Togo. Infection, Genetics and Evolution, 2016, 46, 279-285.	2.3	6

#	ARTICLE	IF	CITATIONS
73	Non-contiguous-Finished Genome Sequence and Description of <i>Paenibacillus camerounensis</i> sp. nov.. <i>Microbial Ecology</i> , 2016, 71, 990-998.	2.8	5
74	<i>Cryptococcus neoformans</i> isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient. <i>Journal of Medical Microbiology</i> , 2016, 65, 579-589.	1.8	10
75	First case of mixed infection with <i>Cryptococcus deuterogattii</i> and <i>Cryptococcus neoformans</i> VNI in an Ivorian HIV-positive patient. <i>JMM Case Reports</i> , 2016, 3, e005037.	1.3	10
76	Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo. <i>AIDS Research and Therapy</i> , 2015, 12, 38.	1.7	6
77	Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. <i>Aids</i> , 2015, 29, 2527-2530.	2.2	16
78	Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 355-364.	2.1	37
79	Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy]. <i>HIV Medicine</i> , 2015, 16, 207-218.	2.2	15
80	Cryptococcal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and <i>Cryptococcus neoformans</i> isolates susceptibility study to fluconazole. <i>Journal De Mycologie Medicale</i> , 2015, 25, 11-16.	1.5	22
81	Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. <i>Aids</i> , 2015, 29, 1473-1481.	2.2	39
82	Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality. <i>BMC Medical Research Methodology</i> , 2015, 15, 10.	3.1	31
83	Molecular characterization of a new mosaic Simian Immunodeficiency Virus in a naturally infected tanzanian monkey ( <i>Chlorocebus tantalus</i> ) from Cameroon: A challenge to the virus-host co-evolution of SIVgm in African green monkeys. <i>Infection, Genetics and Evolution</i> , 2015, 30, 65-73.	2.3	9
84	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1517-1521.	3.0	9
85	Origin of the HIV-1 group O epidemic in western lowland gorillas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1343-52.	7.1	136
86	Assessment of Infections with Microsporidia and <i>Cryptosporidium</i> spp. in Fecal Samples from Wild Primate Populations from Cameroon and Democratic Republic of Congo. <i>International Journal of Primatology</i> , 2015, 36, 227-243.	1.9	5
87	Investigation of minor species <i>Candida africana</i> , <i>Candida stellatoidea</i> and <i>Candida dubliniensis</i> in the <i>Candida albicans</i> complex among Yaoundé (Cameroon) HIV-infected patients. <i>Mycoses</i> , 2015, 58, 33-39.	4.0	26
88	HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges. <i>Infection, Genetics and Evolution</i> , 2015, 36, 210-216.	2.3	22
89	Wild Gorillas as a Potential Reservoir of <i>Leishmania major</i> . <i>Journal of Infectious Diseases</i> , 2015, 211, 267-273.	4.0	25
90	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. <i>Bulletin of the World Health Organization</i> , 2015, 93, 521-528.	3.3	9

#	ARTICLE	IF	CITATIONS
91	Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. <i>Antiviral Therapy</i> , 2014, 19, 51-59.	1.0	13
92	Challenges of Antiretroviral Treatment Monitoring in Rural and Remote-Access Regions in Africa. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 623-625.	1.1	7
93	Full-Length Genome Analyses of Two New Simian Immunodeficiency Virus (SIV) Strains from Mustached Monkeys ( <i>C. Cephus</i> ) in Gabon Illustrate a Complex Evolutionary History among the SIV <sub>mus/mon/gsn</sub> Lineage. <i>Viruses</i> , 2014, 6, 2880-2898.	3.3	11
94	Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the S-tratall ANRS 12110/ESTHER trial in Cameroon. <i>HIV Medicine</i> , 2014, 15, 478-487.	2.2	44
95	High Rates of Infection with Novel Enterovirus Variants in Wild Populations of Mandrills and Other Old World Monkey Species. <i>Journal of Virology</i> , 2014, 88, 5967-5976.	3.4	15
96	Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia. <i>Journal of Clinical Microbiology</i> , 2014, 52, 578-586.	3.9	60
97	Extraordinary Heterogeneity of Virological Outcomes in Patients Receiving Highly Antiretroviral Therapy and Monitored With the World Health Organization Public Health Approach in Sub-Saharan Africa and Southeast Asia. <i>Clinical Infectious Diseases</i> , 2014, 58, 99-109.	5.8	83
98	Co-circulation of enteroviruses between apes and humans. <i>Journal of General Virology</i> , 2014, 95, 403-407.	2.9	33
99	Assessment of gastrointestinal parasites in wild chimpanzees ( <i>Pan troglodytes troglodytes</i> ) in southeast Cameroon. <i>Parasitology Research</i> , 2014, 113, 2541-2550.	1.6	24
100	African origin of the malaria parasite <i>Plasmodium vivax</i> . <i>Nature Communications</i> , 2014, 5, 3346.	12.8	167
101	Non-contiguous finished genome sequence and description of <i>Gorilibacterium massiliense</i> gen. nov, sp. nov., a new member of the family Paenibacillaceae. <i>Standards in Genomic Sciences</i> , 2014, 9, 807-820.	1.5	17
102	Non-contiguous finished genome sequence and description of <i>Paenibacillus gorillae</i> sp. nov.. <i>Standards in Genomic Sciences</i> , 2014, 9, 1031-1045.	1.5	7
103	Detection of Termites and Other Insects Consumed by African Great Apes using Molecular Fecal Analysis. <i>Scientific Reports</i> , 2014, 4, 4478.	3.3	35
104	Pathogenic Eukaryotes in Gut Microbiota of Western Lowland Gorillas as Revealed by Molecular Survey. <i>Scientific Reports</i> , 2014, 4, 6417.	3.3	17
105	Gorilla <i>gorilla gorilla</i> gut: a potential reservoir of pathogenic bacteria as revealed using culturomics and molecular tools. <i>Scientific Reports</i> , 2014, 4, 7174.	3.3	53
106	Intestinal Parasitic Infections in HIV-Infected Patients, Lao People's Democratic Republic. <i>PLoS ONE</i> , 2014, 9, e91452.	2.5	44
107	Origin and diversity of human retroviruses. <i>AIDS Reviews</i> , 2014, 16, 23-34.	1.0	49
108	Nonlinear multiple imputation for continuous covariate within semiparametric Cox model: application to HIV data in Senegal. <i>Statistics in Medicine</i> , 2013, 32, 4651-4665.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. <i>Clinical Infectious Diseases</i> , 2013, 57, 604-607.	5.8	6
110	Laboratory monitoring for antiretroviral therapy in low-resource settings. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 739.	9.1	0
111	Nonhuman primate retroviruses from Cambodia: High simian foamy virus prevalence, identification of divergent STLV-1 strains and no evidence of SIV infection. <i>Infection, Genetics and Evolution</i> , 2013, 18, 325-334.	2.3	18
112	High frequency of HIV-1 infections with multiple HIV-1 strains in men having sex with men (MSM) in Senegal. <i>Infection, Genetics and Evolution</i> , 2013, 20, 206-214.	2.3	14
113	Use of RNAlater® as a preservation method for parasitic coprology studies in wild-living chimpanzees. <i>Experimental Parasitology</i> , 2013, 135, 257-261.	1.2	16
114	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 577-586.	9.1	39
115	A novel multiregion hybridization assay reveals high frequency of dual inter-subtype infections among HIV-positive individuals in Cameroon, West Central Africa. <i>Infection, Genetics and Evolution</i> , 2013, 14, 73-82.	2.3	7
116	Evidence for continuing cross-species transmission of SIVsmm to humans. <i>Aids</i> , 2013, 27, 2488-2491.	2.2	66
117	<i>Plasmodium falciparum</i> -like parasites infecting wild apes in southern Cameroon do not represent a recurrent source of human malaria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7020-7025.	7.1	53
118	Development of a checklist of quality indicators for clinical trials in resource-limited countries: The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience. <i>Clinical Trials</i> , 2013, 10, 300-318.	1.6	7
119	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1388-1399.	3.0	28
120	Genotyping and antifungal susceptibility testing of <i>Cryptococcus neoformans</i> isolates from Cameroonian HIV-positive adult patients. <i>Clinical Microbiology and Infection</i> , 2013, 19, 763-769.	6.0	25
121	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon – Data from the STRATALL ANRS 12110/ESTHER trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 347-355.	1.2	6
122	Successful Integrase Inhibitor-Based Highly Active Antiretroviral Therapy for a Multidrug-Class-Resistant HIV Type 1 Group O-Infected Patient in Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1-3.	1.1	21
123	HIV Type-1 Group O Infection in Gabon: Low Prevalence Rate But Circulation of Genetically Diverse and Drug-Resistant HIV Type-1 Group O Strains. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1085-1090.	1.1	10
124	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1400-1405.	3.0	29
125	Morbidity After Antiretroviral Therapy Initiation in HIV-1-Infected Children in West Africa. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 354-360.	2.0	8
126	Antiretroviral Drugs in Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e74-e76.	2.1	2



#	ARTICLE	IF	CITATIONS
127	Risk of Virological Failure and Drug Resistance During First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 381-387.	2.1	36
128	Universal health coverage and HIV in resource-constrained countries. <i>Aids</i> , 2013, 27, 2173-2175.	2.2	4
129	Task Shifting HIV Care in Rural District Hospitals in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 569-576.	2.1	26
130	Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon. <i>Antiviral Therapy</i> , 2013, 18, 29-37.	1.0	20
131	Virological outcome and patterns of HIV drug resistance in patients with 36 months antiretroviral therapy experience in Cameroon. <i>Journal of the International AIDS Society</i> , 2013, 16, 18004.	3.0	32
132	Susceptibility to Transmitting HIV in Patients Initiating Antiretroviral Therapy in Rural District Hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial). <i>PLoS ONE</i> , 2013, 8, e62611.	2.5	7
133	Molecular Evidence for the Presence of <i>Rickettsia Felis</i> in the Feces of Wild-living African Apes. <i>PLoS ONE</i> , 2013, 8, e54679.	2.5	33
134	Impact of HIV Comprehensive Care and Treatment on Serostatus Disclosure among Cameroonian Patients in Rural District Hospitals. <i>PLoS ONE</i> , 2013, 8, e55225.	2.5	9
135	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon – data from the STRATALL ANRS 12110/ESTHER trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 347-55.	1.2	5
136	Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon. <i>Antiviral Therapy</i> , 2012, 17, 321-326.	1.0	31
137	Noninvasive Follow-Up of Simian Immunodeficiency Virus Infection in Wild-Living Nonhabituated Western Lowland Gorillas in Cameroon. <i>Journal of Virology</i> , 2012, 86, 9760-9772.	3.4	26
138	AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Côte d'Ivoire. <i>Clinical Infectious Diseases</i> , 2012, 54, 714-723.	5.8	84
139	Operational research and HIV policy and guidelines: Lessons from a study of patients lost to follow-up from a public antiretroviral treatment program in Cameroon. <i>Journal of Public Health Policy</i> , 2012, 33, 462-477.	2.0	5
140	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. <i>Aids</i> , 2012, 26, 951-957.	2.2	36
141	CD4-Specific Mortality Rates Among HIV-Infected Adults With High CD4 Counts and No Antiretroviral Treatment in West Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 213-219.	2.1	11
142	HIV laboratory monitoring for effective ART in Africa – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 430-431.	9.1	1
143	Ubiquitous Hepatocystis infections, but no evidence of <i>Plasmodium falciparum</i> -like malaria parasites in wild greater spot-nosed monkeys ( <i>Cercopithecus nictitans</i> ). <i>International Journal for Parasitology</i> , 2012, 42, 709-713.	3.1	18
144	Identification and Molecular Characterization of New Simian T Cell Lymphotropic Viruses in Nonhuman Primates Bushmeat from the Democratic Republic of Congo. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 628-635.	1.1	23

#	ARTICLE	IF	CITATIONS
145	Simian retroviruses in African apes. <i>Clinical Microbiology and Infection</i> , 2012, 18, 514-520.	6.0	30
146	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. <i>BMC Infectious Diseases</i> , 2012, 12, 147.	2.9	7
147	Reduced Quantitative Ultrasound Bone Mineral Density in HIV-Infected Patients on Antiretroviral Therapy in Senegal. <i>PLoS ONE</i> , 2012, 7, e31726.	2.5	19
148	Molecular Epidemiology of Human Immunodeficiency Virus Type 1 in Guangdong Province of Southern China. <i>PLoS ONE</i> , 2012, 7, e48747.	2.5	21
149	Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. <i>Journal of the International AIDS Society</i> , 2012, 15, 17985.	3.0	52
150	Failure to Detect Simian Immunodeficiency Virus Infection in a Large Cameroonian Cohort with High Non-human Primate Exposure. <i>EcoHealth</i> , 2012, 9, 17-23.	2.0	9
151	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. <i>PLoS ONE</i> , 2012, 7, e36118.	2.5	9
152	Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. <i>Isrn Aids</i> , 2012, 2012, 1-8.	2.5	41
153	Origin and Emergence of HIV/AIDS. , 2011, , 689-710.		3
154	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 825-833.	9.1	83
155	Revisiting Long-Term Adherence to Highly Active Antiretroviral Therapy in Senegal Using Latent Class Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 55-61.	2.1	33
156	Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. <i>Aids</i> , 2011, 25, 2183-2188.	2.2	62
157	Adherence to Antiretroviral Treatment in HIV-Positive Patients in the Cameroon Context: Promoting the Use of Medication Reminder Methods. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, S40-S43.	2.1	30
158	Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naïve patients: a 9-year cohort study in Senegal. <i>Tropical Medicine and International Health</i> , 2011, 16, 217-222.	2.3	6
159	Lack of Evidence of Simian Immunodeficiency Virus Infection Among Nonhuman Primates in Taï National Park, Côte d'Ivoire: Limitations of Noninvasive Methods and SIV Diagnostic Tools for Studies of Primate Retroviruses. <i>International Journal of Primatology</i> , 2011, 32, 288-307.	1.9	9
160	Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms. <i>Retrovirology</i> , 2011, 8, 4.	2.0	58
161	High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. <i>Journal of the International AIDS Society</i> , 2011, 14, 30.	3.0	45
162	Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1303-1310.	1.9	16

#	ARTICLE	IF	CITATIONS
163	Prevalence of gastrointestinal parasites in primate bushmeat and pets in Cameroon. <i>Veterinary Parasitology</i> , 2011, 175, 187-191.	1.8	38
164	Novel Multiplexed HIV/Simian Immunodeficiency Virus Antibody Detection Assay. <i>Emerging Infectious Diseases</i> , 2011, 17, 2277-2286.	4.3	29
165	High HIV Type 1 Group M <i>pol</i> Diversity and Low Rate of Antiretroviral Resistance Mutations Among the Uniformed Services in Kinshasa, Democratic Republic of the Congo. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 323-329.	1.1	32
166	High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1635-1641.	3.9	27
167	Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, S27-S33.	2.1	28
168	Detection and Genetic Characterization of Enteroviruses Circulating among Wild Populations of Chimpanzees in Cameroon: Relationship with Human and Simian Enteroviruses. <i>Journal of Virology</i> , 2011, 85, 4480-4486.	3.4	65
169	Characterization of HIV-1 Genotypes and Antiretroviral Drug-resistance Mutations among Patients in Burkina Faso. <i>Pakistan Journal of Biological Sciences</i> , 2011, 14, 392-398.	0.5	8
170	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the leDEA West Africa collaboration. <i>Aids</i> , 2010, 24, 1043-1050.	2.2	31
171	Origin of HIV/AIDS and risk for ongoing zoonotic transmissions from nonhuman primates to humans. <i>HIV Therapy</i> , 2010, 4, 387-390.	0.6	2
172	Reduced dose of stavudine and lipotrophy in HIV-infected patients in Cameroon. <i>Antiviral Therapy</i> , 2010, 15, 1039-1043.	1.0	12
173	Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. <i>BMC Public Health</i> , 2010, 10, 105.	2.9	27
174	Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. <i>Infection, Genetics and Evolution</i> , 2010, 10, 386-396.	2.3	100
175	Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. <i>BMC Infectious Diseases</i> , 2010, 10, 179.	2.9	20
176	High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. <i>HIV Medicine</i> , 2010, 11, 85-89.	2.2	31
177	Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1525-1531.	6.0	38
178	WHO clinical criteria-based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations. <i>Tropical Medicine and International Health</i> , 2010, 15, 580-3.	2.3	6
179	Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 34-42.	2.3	80
180	Origin of the human malaria parasite <i>Plasmodium falciparum</i> in gorillas. <i>Nature</i> , 2010, 467, 420-425.	27.8	445

#	ARTICLE	IF	CITATIONS
181	Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1562-1566.	3.0	60
182	Widespread Infection with Homologues of Human Parvoviruses B19, PARV4, and Human Bocavirus of Chimpanzees and Gorillas in the Wild. <i>Journal of Virology</i> , 2010, 84, 10289-10296.	3.4	73
183	Changes in the Renal Function After Tenofovir-Containing Antiretroviral Therapy Initiation in a Senegalese Cohort (ANRS 1215). <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1221-1227.	1.1	28
184	Full-length genome sequence of a simian immunodeficiency virus (SIV) infecting a captive agile mangabey ( <i>Cercocebus agilis</i> ) is closely related to SIVrcm infecting wild red-capped mangabeys ( <i>Cercocebus torquatus</i> ) in Cameroon. <i>Journal of General Virology</i> , 2010, 91, 2959-2964.	2.9	13
185	African great apes are natural hosts of multiple related malaria species, including <i>Plasmodium falciparum</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 1458-1463.	7.1	229
186	Molecular Epidemiology of Simian Immunodeficiency Virus Infection in Wild-Living Gorillas. <i>Journal of Virology</i> , 2010, 84, 1464-1476.	3.4	78
187	Call for action to secure universal access to ART in developing countries. <i>Lancet</i> , 2010, 375, 1693-1694.	13.7	8
188	Genetic diversity of simian lentivirus in wild De Brazza's monkeys ( <i>Cercopithecus neglectus</i> ) in Equatorial Africa. <i>Journal of General Virology</i> , 2010, 91, 1810-1816.	2.9	6
189	Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. <i>Open AIDS Journal</i> , 2009, 3, 63-70.	0.5	10
190	Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon. <i>PLoS ONE</i> , 2009, 4, e7702.	2.5	72
191	Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, CÔte d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1193-1196.	1.1	40
192	CRF45_AKU, a Circulating Recombinant from Central Africa, Is Probably the Common Ancestor of HIV Type 1 MAL and HIV Type 1 NOGIL. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1345-1353.	1.1	10
193	Full-Length Genome Characterization of a Novel Simian Immunodeficiency Virus Lineage (SIVolc) from Olive Colobus ( <i>Procolobus verus</i> ) and New SIVwrcPbb Strains from Western Red Colobus ( <i>Ptilocolobus badius badius</i> ) from the Tail Forest in Ivory Coast. <i>Journal of Virology</i> , 2009, 83, 428-439.	3.4	30
194	Genetic Characterization of Eight Full-Length HIV Type 1 Genomes from the Democratic Republic of Congo (DRC) Reveal a New Subsubtype, A5, in the A Radiation That Predominates in the Recombinant Structure of CRF26_A5U. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 823-832.	1.1	21
195	Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naïve Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009, 8, 379-384.	1.2	13
196	Low Levels of Antiretroviral-Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second-Line Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, 1318-1322.	5.8	62
197	Evaluation of Different RNA Extraction Methods and Storage Conditions of Dried Plasma or Blood Spots for Human Immunodeficiency Virus Type 1 RNA Quantification and PCR Amplification for Drug Resistance Testing. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1107-1118.	3.9	98
198	Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naïve patients. <i>Infection, Genetics and Evolution</i> , 2009, 9, 646-652.	2.3	21

#	ARTICLE	IF	CITATIONS
199	Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. <i>Aids</i> , 2009, 23, 977-985.	2.2	24
200	Lipodystrophy and Metabolic Disorders in HIV-1-Infected Adults on 4- to 9-Year Antiretroviral Therapy in Senegal: A Case-Control Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 224-230.	2.1	59
201	Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. <i>Antiviral Therapy</i> , 2009, 14, 401-11.	1.0	28
202	Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. <i>Antiviral Therapy</i> , 2009, 14, 401-411.	1.0	42
203	Change over time of mortality predictors after HAART initiation in a Senegalese cohort. <i>European Journal of Epidemiology</i> , 2008, 23, 227-234.	5.7	11
204	Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). <i>Journal of Medical Virology</i> , 2008, 80, 1332-1336.	5.0	76
205	Prevalence and genetic diversity of simian immunodeficiency virus infection in wild-living red colobus monkeys ( <i>Ptilocolobus badius badius</i> ) from the Taï forest, Côte d'Ivoire. <i>Infection, Genetics and Evolution</i> , 2008, 8, 1-14.	2.3	25
206	Identification and molecular characterization of new STLV-1 and STLV-3 strains in wild-caught nonhuman primates in Cameroon. <i>Virology</i> , 2008, 371, 405-417.	2.4	45
207	Full molecular characterization of a simian immunodeficiency virus, SIVwrcpbt from Temminck's red colobus ( <i>Ptilocolobus badius temminckii</i> ) from Abuko Nature Reserve, The Gambia. <i>Virology</i> , 2008, 376, 90-100.	2.4	23
208	Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 753-760.	1.1	22
209	Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 283-293.	2.4	25
210	Molecular Tracing of Sexual HIV Type 1 Transmission in the Southwest Border of China. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 733-742.	1.1	22
211	Tolerability and Effectiveness of First-Line Regimens Combining Nevirapine and Lamivudine Plus Zidovudine or Stavudine in Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 393-400.	1.1	32
212	DIAGNOSTIC APPROACHES TO IMPORTED SCHISTOSOMAL MYELOGRANULOPATHY IN TRAVELERS. <i>Neurology</i> , 2008, 71, 66-67.	1.1	11
213	Characterization of an Old Complex Circulating Recombinant Form, CRF27_cpx, Originating from the Democratic Republic of Congo (DRC) and Circulating in France. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 315-321.	1.1	15
214	Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring and Self-Report in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 216-219.	2.1	25
215	The marriage of science and optimized HIV care in resource-limited settings. <i>Aids</i> , 2008, 22, 2227-2230.	2.2	4
216	Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. <i>Aids</i> , 2007, 21, 768-771.	2.2	29

#	ARTICLE	IF	CITATIONS
217	HIV Type 1 Diversity and Antiretroviral Drug Resistance Mutations in Burundi. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 175-180.	1.1	21
218	HIV and Hepatitis C Virus Coinfection, Cameroon. <i>Emerging Infectious Diseases</i> , 2007, 13, 514-516.	4.3	19
219	Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. <i>Journal of the International AIDS Society</i> , 2007, 9, 7-7.	3.0	0
220	A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. <i>Tropical Medicine and International Health</i> , 2007, 12, 1191-1198.	2.3	35
221	Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. <i>HIV Medicine</i> , 2007, 8, 92-95.	2.2	38
222	Full-length sequence analysis of SIVmus in wild populations of mustached monkeys ( <i>Cercopithecus</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 407-418.	2.4	43
223	Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. <i>Virology</i> , 2007, 368, 155-171.	2.4	118
224	Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. <i>MedGenMed: Medscape General Medicine</i> , 2007, 9, 7.	0.2	2
225	Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. <i>Science</i> , 2006, 313, 523-526.	12.6	723
226	Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. <i>Journal of Clinical Virology</i> , 2006, 36, 43-49.	3.1	66
227	Antiretroviral Drug Resistance and Routine Therapy, Cameroon. <i>Emerging Infectious Diseases</i> , 2006, 12, 1001-1004.	4.3	25
228	Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. <i>Aids</i> , 2006, 20, 1181-1189.	2.2	240
229	Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 46, 53-62.	2.7	41
230	SIV infection in wild gorillas. <i>Nature</i> , 2006, 444, 164-164.	27.8	315
231	HIV-1 subtypes and recombinants in the Republic of Congo. <i>Infection, Genetics and Evolution</i> , 2006, 6, 337-343.	2.3	46
232	Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. <i>Virology</i> , 2006, 345, 174-189.	2.4	52
233	Molecular characterization of a novel simian immunodeficiency virus lineage (SIVtal) from northern talapoin ( <i>Miopithecus ogouensis</i> ). <i>Virology</i> , 2006, 349, 55-65.	2.4	21
234	HIV Type 1 pol Gene Diversity and Antiretroviral Drug Resistance Mutations in the Democratic Republic of Congo (DRC). <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 202-206.	1.1	45

#	ARTICLE	IF	CITATIONS
235	Identification and Molecular Characterization of Subsubtype A4 in Central Africa. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 182-187.	1.1	27
236	Phylogenetic Analysis of Brazilian HIV Type 1 Subtype D Strains: Tracing the Origin of This Subtype in Brazil. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 207-211.	1.1	25
237	PREVALENCE OF INTESTINAL PARASITES INCLUDING MICROSPORIDIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED ADULTS IN CAMEROON: A CROSS-SECTIONAL STUDY. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 74, 162-164.	1.4	87
238	Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 74, 162-4.	1.4	45
239	HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. <i>Antiviral Therapy</i> , 2006, 11, 575-9.	1.0	17
240	HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon. <i>Antiviral Therapy</i> , 2006, 11, 575-579.	1.0	47
241	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. <i>Journal of Experimental Medicine</i> , 2005, 201, 1407-1419.	8.5	296
242	Antiretroviral Therapy in Public and Private Routine Health Care Clinics in Cameroon: Lessons from the Douala Antiretroviral (DARVIR) Initiative. <i>Clinical Infectious Diseases</i> , 2005, 41, 108-111.	5.8	37
243	Enfuvirtide Binding Domain Is Highly Conserved in Non-B HIV Type 1 Strains from Cameroon, West Central Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 430-433.	1.1	22
244	Presence of CRF09_cpx and Complex CRF02_AG/CRF09_cpx Recombinant HIV Type 1 Strains in CÔte d'Ivoire, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 667-672.	1.1	16
245	Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 14-17.	2.1	147
246	Distribution of HIV-1 Variants in the Democratic Republic of Congo Suggests Increase of Subtype C in Kinshasa Between 1997 and 2002. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 456-462.	2.1	61
247	Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. <i>Antiviral Therapy</i> , 2005, 10, 335-41.	1.0	15
248	Field Assessment of Generic Antiretroviral Drugs: A Prospective Cohort Study in Cameroon. <i>Antiviral Therapy</i> , 2005, 10, 335-341.	1.0	40
249	Commercial Logging and HIV Epidemic, Rural Equatorial Africa. <i>Emerging Infectious Diseases</i> , 2004, 10, 1953-1956.	4.3	15
250	New Simian Immunodeficiency Virus Infecting De Brazza's Monkeys ( <i>Cercopithecus neglectus</i> ): Evidence for a <i>Cercopithecus</i> Monkey Virus Clade. <i>Journal of Virology</i> , 2004, 78, 7748-7762.	3.4	121
251	Evaluation of Four Simple/Rapid Assays and Two Fourth-Generation ELISAs for the Identification of HIV Infection on a Serum Panel Representing the HIV-1 Group M Genetic Diversity in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1632-1640.	2.1	32
252	Simian T-Cell Leukemia Virus (STLV) Infection in Wild Primate Populations in Cameroon: Evidence for Dual STLV Type 1 and Type 3 Infection in Agile Mangabey ( <i>Cercocebus agilis</i> ). <i>Journal of Virology</i> , 2004, 78, 4700-4709.	3.4	62

#	ARTICLE	IF	CITATIONS
253	Complete Genome Analysis of One of the Earliest SIVcpzPtt Strains from Gabon (SIVcpzGAB2). <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1377-1381.	1.1	22
254	Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. <i>Lancet</i> , The, 2004, 364, 29-34.	13.7	271
255	HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. <i>Aids</i> , 2004, 18, 1645-1651.	2.2	45
256	Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 329-336.	2.1	40
257	Political and socioeconomic instability. <i>Aids</i> , 2004, 18, 832-834.	2.2	24
258	Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. <i>Virology</i> , 2003, 310, 254-266.	2.4	95
259	Emergence of Complex and Diverse CRF02-AG/CRF06-cpx Recombinant HIV Type 1 Strains in Niger, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 77-82.	1.1	25
260	Identification of a New Simian Immunodeficiency Virus Lineage with a vpu Gene Present among Different Cercopithecus Monkeys ( <i>C. mona</i> , <i>C. cephus</i> , and <i>C. nictitans</i> ) from Cameroon. <i>Journal of Virology</i> , 2003, 77, 12523-12534.	3.4	85
261	Partial Molecular Characterization of Two Simian Immunodeficiency Viruses (SIV) from African Colobids: SIVwrc from Western Red Colobus ( <i>Ptilocolobus badius</i> ) and SIVolc from Olive Colobus ( <i>Procolobus verreauxi</i> ). <i>Journal of Virology</i> , 2003, 77, 12535-12541.	1.0	14
262	Adherence to HAART and its principal determinants in a cohort of Senegalese adults. <i>Aids</i> , 2003, 17, S103-S108.	2.2	131
263	Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. <i>Aids</i> , 2003, 17, 1017-1022.	2.2	79
264	Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal. <i>Aids</i> , 2003, 17, 1811-1816.	2.2	50
265	Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. <i>Aids</i> , 2003, 17, S31-S38.	2.2	39
266	Access to antiretroviral drugs and AIDS management in Senegal. <i>Aids</i> , 2003, 17, S95-S101.	2.2	37
267	High Genetic Diversity of HIV-1 Strains in Chad, West Central Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 239-246.	2.1	39
268	CRF06-cpx is the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. <i>Aids</i> , 2003, 17, 441-442.	2.2	22
269	High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. <i>Aids</i> , 2003, 17, 1105-1107.	2.2	7
270	Identification of a New Circulating Recombinant Form of HIV Type 1, CRF11-cpx, Involving Subtypes A, G, J, and CRF01-AE, in Central Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 231-236.	1.1	40



#	ARTICLE	IF	CITATIONS
271	Development and Evaluation of a DNA Enzyme Immunoassay Method for env Genotyping of Subtypes A through G of Human Immunodeficiency Virus Type 1 Group M, with Discrimination of the Circulating Recombinant Forms CRF01_AE and CRF02_AG. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1010-1022.	3.9	14
272	No Difference in Clinical Progression between Patients Infected with the Predominant Human Immunodeficiency Virus Type 1 Circulating Recombinant Form (CRF) 02_AG Strain and Patients Not Infected with CRF02_AG, in Western and West-Central Africa: A Four-Year Prospective Multicenter Study. <i>Journal of Infectious Diseases</i> , 2002, 186, 486-492.	4.0	59
273	Characterization of a Novel Simian Immunodeficiency Virus with a vpu Gene from Greater Spot-Nosed Monkeys ( <i>Cercopithecus nictitans</i> ) Provides New Insights into Simian/Human Immunodeficiency Virus Phylogeny. <i>Journal of Virology</i> , 2002, 76, 8298-8309.	3.4	124
274	The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. <i>Aids</i> , 2002, 16, 1363-1370.	2.2	225
275	CRF06-cpx: A New Circulating Recombinant Form of HIV-1 in West Africa Involving Subtypes A, G, K, and J. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 522-530.	2.1	50
276	Resistance to Antiretroviral Treatment in Gabon: Need for Implementation of Guidelines on Antiretroviral Therapy Use and HIV-1 Drug Resistance Monitoring in Developing Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 165-168.	2.1	68
277	Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 723-726.	1.1	32
278	Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat. <i>Emerging Infectious Diseases</i> , 2002, 8, 451-457.	4.3	240
279	A simple clinical and paraclinical score predictive of CD4 cell counts below 400/mm <sup>3</sup> in HIV-infected adults in Dakar University Hospital, Senegal. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2002, 96, 167-172.	1.8	1
280	Resistance to Antiretroviral Treatment in Gabon: Need for Implementation of Guidelines on Antiretroviral Therapy Use and HIV-1 Drug Resistance Monitoring in Developing Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 165-168.	2.1	0
281	Full-Length Genome Sequencing of HIV Type 1 Group O Viruses Isolated from a Heterosexual Transmission Cluster in Senegal. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1211-1216.	1.1	11
282	Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo. <i>International Journal of Epidemiology</i> , 2001, 30, 872-877.	1.9	67
283	Evaluation of Two Commercial Kits for the Detection of Genotypic Drug Resistance on a Panel of HIV Type 1 Subtypes A Through J. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 254-258.	2.1	41
284	Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes by using a new method to uncover clock-like molecular evolution. <i>FASEB Journal</i> , 2001, 15, 276-278.	0.5	111
285	Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV-1-Infected Patients With Failure of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 36-43.	2.1	55
286	Evidence for a Second Simian T-Cell Lymphotropic Virus Type 3 in <i>Cercopithecus nictitans</i> from Cameroon. <i>Journal of Virology</i> , 2001, 75, 11939-11941.	3.4	26
287	Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. <i>Sexually Transmitted Infections</i> , 2001, 77, 190-193.	1.9	30
288	Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 855-866.	4.0	82

#	ARTICLE	IF	CITATIONS
289	Characterization of a Novel Simian Immunodeficiency Virus from Guereza Colobus Monkeys ( <i>Colobus</i> ) Tj ETQq1 1 2001, 75, 857-866.	0.784314 3.4	102
290	Most env and gag Subtype A HIV-1 Viruses Circulating in West and West Central Africa Are Similar to the Prototype AG Recombinant Virus IBNG. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 363-374.	2.1	100
291	HIV Infection Does Not Explain Elevation of Glycated Hemoglobin among Non-Diabetic Patients in Gabon. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 673.	2.3	3
292	Most env and gag Subtype A HIV-1 Viruses Circulating in West and West Central Africa Are Similar to the Prototype AG Recombinant Virus IBNG. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 363-374.	2.1	95
293	Sequence Note: Identification of All HIV Type 1 Group M Subtypes in Senegal, a Country with Low and Stable Seroprevalence. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 603-609.	1.1	66
294	Predominance of Subtype A and G HIV Type 1 in Nigeria, with Geographical Differences in Their Distribution. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 315-325.	1.1	79
295	Unprecedented Degree of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Genetic Diversity in the Democratic Republic of Congo Suggests that the HIV-1 Pandemic Originated in Central Africa. <i>Journal of Virology</i> , 2000, 74, 10498-10507.	3.4	295
296	Identification of a Complex env Subtype E HIV Type 1 Virus from the Democratic Republic of Congo, Recombinant with A, G, H, J, K, and Unknown Subtypes. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 2059-2064.	1.1	34
297	Near-Full-Length Genome Sequencing of Divergent African HIV Type 1 Subtype F Viruses Leads to the Identification of a New HIV Type 1 Subtype Designated K. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 139-151.	1.1	88
298	Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3919-3925.	3.9	169
299	Prevalence and genetic variants of hepatitis GB-C/HG and TT viruses in Gabon, equatorial Africa.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2000, 63, 192-198.	1.4	13
300	Evidence for Differences in MT2 Cell Tropism According to Genetic Subtypes of HIV-1: Syncytium-Inducing Variants Seem Rare Among Subtype C HIV-1 Viruses. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 115-121.	0.3	119
301	Sequence Note The Identification of a Complex A/G/I/J Recombinant HIV Type 1 Virus in Various West African Countries. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1707-1712.	1.1	37
302	Genetic Characterization of the nef Gene from Human Immunodeficiency Virus Type 1 Group M Strains Representing Genetic Subtypes A, B, C, E, F, G, and H. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 23-32.	1.1	26
303	High Diversity of HIV-1 Subtype F Strains in Central Africa. <i>Virology</i> , 1999, 259, 99-109.	2.4	67
304	V3 Serotyping of HIV-1 Infection: Correlation With Genotyping and Limitations. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 432-441.	0.3	21
305	Interpatient genetic variability of HIV-1 group O. <i>Aids</i> , 1999, 13, 41-48.	2.2	33
306	Characterization of a Highly Replicative Intergroup M/O Human Immunodeficiency Virus Type 1 Recombinant Isolated from a Cameroonian Patient. <i>Journal of Virology</i> , 1999, 73, 7368-7375.	3.4	99

#	ARTICLE	IF	CITATIONS
307	Two New Human T-Lymphotropic Virus Type I Phylogenetic Subtypes in Seroindeterminates, a Mbuti Pygmy and a Gabonese, Have Closest Relatives among African STLV-I Strains. <i>Virology</i> , 1998, 246, 277-287.	2.4	80
308	Clinical algorithms for the screening of pregnant women for STDs in Libreville, Gabon: which alternatives?. <i>Sexually Transmitted Infections</i> , 1998, 74, 35-39.	1.9	12
309	Genetic Subtypes of HIV Type 1 and HIV Type 2 Strains in Commercial Sex Workers from Bamako, Mali. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 51-58.	1.1	104
310	Short Communication: Molecular Characterization of the Envelope Transmembrane Glycoprotein of 13 New Human Immunodeficiency Virus Type 1 Group O Strains from Six Different African Countries. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1281-1285.	1.1	23
311	Genetic Characterization of Accessory Genes from Human Immunodeficiency Virus Type 1 Group O Strains. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 951-961.	1.1	22
312	Short Communication: Multiply Spliced <i>env</i> and <i>nef</i> Transcripts of Simian Immunodeficiency Virus from West African Green Monkey (SIVagm-sab). <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 515-519.	1.1	1
313	Evidence of stable HIV seroprevalences in selected populations in the Democratic Republic of the Congo. <i>Aids</i> , 1998, 12, 905-910.	2.2	30
314	Complete nucleotide sequence of an African human T-lymphotropic virus type II subtype b isolate (HTLV-II-Gab): molecular and phylogenetic analysis.. <i>Journal of General Virology</i> , 1998, 79, 269-277.	2.9	13
315	Geographical distribution of HIV-1 group O viruses in Africa. <i>Aids</i> , 1997, 11, 493-498.	2.2	135
316	Presence of multiple non-B subtypes and divergent subtype B strains of HIV-1 in individuals infected after overseas deployment. <i>Aids</i> , 1997, 11, 43-51.	2.2	105
317	Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. <i>Journal of Medical Virology</i> , 1997, 52, 1-7.	5.0	77
318	Seroprevalence of HIV-1, HIV-2, and HIV-1 Group O in Nigeria: Evidence for a Growing Increase of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 204-210.	0.3	34
319	Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994. <i>Aids</i> , 1996, 10, 903-910.	2.2	65
320	Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. , 1996, 50, 293-302.		112
321	Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. <i>Journal of Medical Virology</i> , 1996, 50, 293-302.	5.0	7
322	Mother-to-Child Transmission of Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/II) in Gabon: A Prospective Follow-up of 4 Years. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 12, 187-192.	0.3	66
323	HTLV-I Infection Among Prostitutes and Pregnant Women in Kinshasa, Zaïre. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 8, 511-515.	0.3	22
324	Evidence for HIV-1 group O infection in Nigeria. <i>Lancet</i> , The, 1995, 346, 308.	13.7	16

#	ARTICLE	IF	CITATIONS
325	Genetic and Phylogenetic Analysis of <i>env</i> Subtypes G and H in Central Africa. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 877-879.	1.1	106
326	Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). <i>Journal of General Virology</i> , 1994, 75, 2393-2398.	2.9	97
327	Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon. <i>Aids</i> , 1994, 8, 1012.	2.2	32
328	Isolation of Simian Immunodeficiency Viruses from Two Sooty Mangabeys in CÔte d'Ivoire: Virological and Genetic Characterization and Relationship to Other HIV Type 2 and SIVsm/mac Strains. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1289-1294.	1.1	52
329	<i>Mycobacterium ulcerans</i> Associated with Infection Due to the Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1994, 18, 839-839.	5.8	14
330	Demographic Factors Associated with HTLV-1 Infection in a Gabonese Community. <i>International Journal of Epidemiology</i> , 1994, 23, 812-817.	1.9	25
331	Genetic and Antigenic Variability of HIV Type 1 in Brazil. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1157-1163.	1.1	18
332	Hepatitis C virus antibodies in prostitutes in Niger. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 536.	1.8	5
333	High prevalence of anti-hepatitis C virus antibodies in a Cameroon rural forest area. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 53-54.	1.8	41
334	Hepatitis C in remote populations of southern Cameroon. <i>Annals of Tropical Medicine and Parasitology</i> , 1994, 88, 97-98.	1.6	16
335	Treatment Regimens of STD Patients in Cameroon. <i>Sexually Transmitted Diseases</i> , 1994, 21, 124.	1.7	15
336	Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. <i>Aids</i> , 1994, 8, 1657-1662.	2.2	18
337	Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 10134-10138.	7.1	143
338	Non-hodgkin lymphoma in gabon and its relation to HTLV-I. <i>International Journal of Cancer</i> , 1993, 53, 48-50.	5.1	13
339	Population-based study of serum hepatitis B virus DNA in Gabon. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1993, 87, 539-540.	1.8	12
340	High level of hepatitis C endemicity in Gabon, equatorial Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1993, 87, 636-637.	1.8	47
341	HTLV-II among Pygmies from Cameroon. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 707-707.	1.1	42
342	Absence of a Relationship between Antibodies to Hepatitis C Virus and Hepatocellular Carcinoma in Mozambique. <i>American Journal of Tropical Medicine and Hygiene</i> , 1993, 48, 237-242.	1.4	21

#	ARTICLE	IF	CITATIONS
343	Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in CÔte d'Ivoire. <i>Lancet, The</i> , 1992, 340, 339-340.	13.7	72
344	Low rate of hepatitis C virus antibodies in blood donors and pregnant women from Niger. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1992, 86, 553.	1.8	11
345	Rapid spread of HIV infections in Abidjan, Ivory Coast, 1987-1990. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1992, 11, 271-273.	2.9	11
346	Humoral responses against the 85A and 85B antigens of <i>Mycobacterium bovis</i> BCG in patients with leprosy and tuberculosis. <i>Journal of Clinical Microbiology</i> , 1992, 30, 1608-1610.	3.9	25
347	Human T-cell lymphotropic virus type I infection and pregnancy: A case-control study and 12-month follow-up of 135 women and their infants. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 165, 1438-1443.	1.3	7
348	Congenital hydrocephalus due to intrauterine HTLV-I infection. <i>Lancet, The</i> , 1991, 337, 248.	13.7	17
349	Human T-cell lymphotropic virus type I infection and pregnancy: A case-control study and 12-month follow-up of 135 women and their infants. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 165, 1438-1443.	1.3	5
350	Prevalence and transmission of simian immunodeficiency virus and simian T-cell leukemia virus in a semi-free-range breeding colony of mandrills in Gabon. <i>Aids</i> , 1991, 5, 1385.	2.2	25
351	Prevalence of HTLV-I and HTLV-II infection in gabon, africa: Comparison of the serological and pcr results. <i>International Journal of Cancer</i> , 1991, 49, 373-376.	5.1	59
352	Age-related prevalence of antibody response against three different, defined <i>Plasmodium falciparum</i> antigens in children from the Haut-Ogooué province in Gabon. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1989, 83, 147-151.	1.8	23
353	Antibody prevalence against haemorrhagic fever viruses in randomized representative central African populations. <i>Research in Virology</i> , 1989, 140, 319-331.	0.7	87
354	Interpretation of antibodies reacting solely with human retroviral core proteins in western equatorial Africa. <i>Aids</i> , 1989, 3, 179-182.	2.2	14
355	Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. <i>Aids</i> , 1989, 3, 625-630.	2.2	217
356	Differentiation between HIV-1 and HIV-2 infection by radioimmunoprecipitation and synthetic peptides in double reactive sera. <i>Aids</i> , 1989, 3, 401.	2.2	10
357	Epidemiology of HTLV-i in gabon (western equatorial Africa). <i>International Journal of Cancer</i> , 1988, 42, 687-689.	5.1	73
358	Short communication Detection of HIV-2 antibodies using five commercial HIV enzyme immunoassays. <i>Aids</i> , 1988, 2, 389-390.	2.2	6
359	Human T-Cell leukemia virus type I isolates from Gabon and Ghana: Comparative analysis of proviral genomes. <i>Virology</i> , 1987, 161, 315-320.	2.4	26
360	Epidemiology of HIV1 infection among randomized representative Central African populations. <i>Annales De L'Institut Pasteur Virology</i> , 1987, 138, 503-510.	0.5	9